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Multiple, complex molecular events characterize cancer develop-
ment and progression1,2. Deciphering the molecular networks that
distinguish organ-confined disease from metastatic disease may
lead to the identification of critical biomarkers for cancer invasion
and disease aggressiveness. Although gene and protein expression
have been extensively profiled in human tumours, little is known
about the global metabolomic alterations that characterize neo-
plastic progression. Using a combination of high-throughput
liquid-and-gas-chromatography-based mass spectrometry, we
profiled more than 1,126 metabolites across 262 clinical samples
related to prostate cancer (42 tissues and 110 each of urine and
plasma). These unbiased metabolomic profiles were able to distin-
guish benign prostate, clinically localized prostate cancer and
metastatic disease. Sarcosine, an N-methyl derivative of the amino
acid glycine, was identified as a differential metabolite that was
highly increased during prostate cancer progression to metastasis
and can be detected non-invasively in urine. Sarcosine levels were
also increased in invasive prostate cancer cell lines relative to
benign prostate epithelial cells. Knockdown of glycine-N-methyl
transferase, the enzyme that generates sarcosine from glycine, atte-
nuated prostate cancer invasion. Addition of exogenous sarcosine
or knockdown of the enzyme that leads to sarcosine degradation,
sarcosine dehydrogenase, induced an invasive phenotype in benign
prostate epithelial cells. Androgen receptor and the ERG gene
fusion product coordinately regulate components of the sarcosine
pathway. Here, by profiling the metabolomic alterations of prostate
cancer progression, we reveal sarcosine as a potentially important
metabolic intermediary of cancer cell invasion and aggressivity.
To profile the ‘metabolome’ during prostate cancer progression, we
used both liquid and gas chromatography coupled with mass spec-
trometry3 to interrogate the relative levels of metabolites across 262
prostate-related biospecimens (outlined in Supplementary Fig. 1).
Specifically, 42 tissue samples and 110 matched specimens of plasma
and post-digital-rectal-exam urine from biopsy-positive cancer
patients (n 5 59) and biopsy-negative control individuals (n 5 51)
were assayed (Fig. 1a). A total of 1,126 metabolites were quantified
and, as expected, only a small percentage of these metabolites (15.6%)
were shared across the disparate biospecimen types (Fig. 1a).
Evaluation of the unbiased metabolomic profiles of plasma or
urine did not identify robust differences between biopsy-positive
and -negative individuals. For plasma, 20 out of 478 (4%) metabolites
were differential (Wilcoxon P , 0.05), with a false discovery rate
(FDR) of 99%. Likewise, for urine, 36 out of 583 (6%) metabolites
were differential (Wilcoxon P , 0.05), with an FDR of 67%. Thus, our
initial focus was directed towards understanding the tissue metabo-
lomic profiles as they showed more robust alterations.
Tissue samples were derived from benign adjacent prostate
(n 5 16), clinically localized prostate cancer (n 5 12, PCA) and meta-
static prostate cancer (n 5 14) patients. Selection of metastatic tissue
samples from different sites (see Supplementary Table 2) minimized
characterization of analytes specific to cells of non-prostatic origin. In
total, high-throughput profiling of the tissues quantitatively detected
626 metabolites (175 named, 19 isobars and 432 metabolites without
identification), of which 82.3% (515 out of 626) were shared by the
three diagnostic classes (Fig. 1b). Notably, there were 60 metabolites
found in PCA and/or metastatic tumours but not in benign prostate.
These profiles were displayed as a heat map (Fig. 1c) and z-score plot
(Fig. 1d). In the latter, benign-based z-scores were plotted for each of
the 626 metabolites. The plots revealed robust metabolic alterations in
metastatic tumours (z-score range: 213.6 to 81.9) compared to fewer
changes in clinically localized prostate cancer samples (z-score range:
27.7 to 45.8).
We identified the differential metabolites between the PCA and
benign samples using a two-sided Wilcoxon rank-sum test coupled
with a permutation test (n 5 1,000). A total of 87 out of 518 metabo-
lites were differential across these two classes (P , 0.05, corresponding
to a 23% FDR). For visualizing the relationship between the 87 altered
metabolites, hierarchical clustering was used to arrange the metabo-
lites on the basis of their relative levels across samples (Fig. 2a). Among
the perturbed metabolites, 50 were increased in PCA samples whereas
37 were downregulated. Figure 2b displays the relative levels of the 37
named metabolites that were differential between benign prostate and
PCA samples. Similarly, 124 out of 518 metabolites were found to be
increased in the metastatic samples compared to the localized
tumours and 102 compounds were downregulated (P , 0.05, corres-
ponding to a 4% FDR). Figure 2c displays the levels of the 91 named
metabolites altered in metastatic samples. A subset of six metabolites
including sarcosine, uracil, kynurenine, glycerol-3-phosphate, leucine
and proline were significantly increased on disease progression from
benign to PCA to metastatic prostate cancer. These metabolites could
potentially serve as biomarkers for progressive disease, one of the
factors that motivated us to examine sarcosine in greater detail.
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Mapping the differential metabolomic profiles to their respective
biochemical pathways as outlined in the Kyoto Encyclopedia of Genes
and Genomes (KEGG, release 41.1, http://www.genome.jp/kegg,
Supplementary Fig. 8) revealed an increase in amino acid metabolism
and nitrogen breakdown pathways during cancer progression to meta-
static disease. A similar enrichment network of amino acid metabo-
lism was also identified by the bioinformatics tool Oncomine Concept
Map4,5(OCM, http://www.oncomine.org, P 5 6 3 10213, Supple-
mentary Figs 9 and 10a), supporting our earlier gene-expression-
based prediction of androgen-induced protein synthesis as an early
event during prostate cancer development5. Additionally, OCM found
strong enrichment for increased ‘methyltransferase activity’
(Supplementary Fig. 10b, P 5 7.7 3 1028) among metabolites upre-
gulated in metastatic samples. This corroborates previous studies from
our group and others showing an increase of the histone methyltrans-
ferase EZH2 in metastatic tumours6–11.
Because amino acid metabolism and methylation were enriched
during prostate cancer progression, we focused on differential meta-
bolites that characterize these processes and additionally show a pro-
gressive increase from benign to PCA to metastatic disease. The
amino acid metabolite sarcosine, an N-methyl derivative of glycine,
fits these criteria. Notably, metastatic samples showed markedly
increased levels of sarcosine in 79% of the specimens analysed (chi-
squared test, P 5 0.0538), whereas 42% of the PCA samples showed
an increase in the levels of this metabolite (Fig. 2a–c). Importantly,
none of the benign samples had detectable levels of sarcosine. Taken
together, this indicated the possible utility of sarcosine in monitoring
disease progression and aggressiveness.
To confirm this pattern of sarcosine increase in cancer progression,
we developed a highly sensitive and specific isotope dilution gas
chromatography–mass spectrometry (GC–MS) method for accurately
quantifying the metabolite from biospecimens (limit of detec-
tion 5 10 femtomoles, Supplementary Fig. 11). In an independent
set of 89 tissue samples (Supplementary Table 6), sarcosine levels were
significantly increased in PCA specimens (n 5 36) compared to benign
adjacent prostate samples (n 5 25, Wilcoxon P 5 4.34 3 10211,
Fig. 3a). Additionally, there was an even greater increase of sarcosine
in metastatic samples (n 5 28) compared to organ-confined disease
(Wilcoxon P 5 6.02 3 10211, Fig. 3a). In contrast, sarcosine was unde-
tectable in adjacent non-neoplastic tissues from patients with meta-
static disease (Supplementary Fig. 12a–c).
These findings led us to explore the potential of sarcosine as a
candidate for future development in biomarker panels for early disease
detection and aggressivity prediction. Towards this end, we monitored
its levels in urine specimens from biopsy-positive and -negative
individuals, most of whom have increased levels of prostate-specific
antigen (PSA) (.4.0 ng ml21) and in which prostate needle biopsy was
used for diagnosis. This is a particularly challenging cohort as, in
addition to these men being at high risk for prostate cancer, even a
negative needle biopsy does not rule out the presence of cancer due to
sampling issues. Sarcosine was found to be significantly higher in urine
sediments (n 5 49, Wilcoxon P 5 0.0004, Fig. 3b) and supernatants
(n 5 59, Wilcoxon P 5 0.0025, Supplementary Fig. 14a) derived from
biopsy-positive prostate cancer patients compared to biopsy-negative
controls (n 5 44 and n 5 51, respectively; Supplementary Tables 7
and 8). The overall receiver operating characteristic curves for sarco-
sine indicate that its predictive value is modest, with an area under the
curve (AUC) of 0.71 for urine sediments and 0.67 for supernatants
(Supplementary Fig. 14b, c). Notably, an AUC of 1.0 indicates perfect
prediction and an AUC of 0.5 indicates prediction equivalent to
random selection. When restricted to samples having PSA in the
clinical grey zone of 2–10 ng ml21 (n 5 53), sarcosine performed
better than PSA in delineating the two diagnostic classes with an
AUC of 0.69 (95% CI: 0.55, 0.84) compared to an AUC of 0.53
(95% CI: 0.37, 0.69) for PSA (Supplementary Fig. 15). Thus, sarcosine
may have the potential to identify patients with modestly increased
PSA that are likely to have a positive prostate biopsy.
To determine whether the sarcosine increase in prostate cancer has
biological relevance, we measured its levels in prostate cancer cell lines
VCaP, DU145, 22RV1 and LNCaP (n 5 3 each) as well as in their
benign epithelial counterparts, primary benign prostate epithelial cells
(PrEC, n 5 2) and immortalized benign RWPE prostate cells (n 5 3).
Significantly increased levels of the metabolite were found in prostate
cancer cells compared to the benign cells (analysis of variance,
ANOVA, P 5 0.0218, Fig. 3c). Additionally, sarcosine levels correlated
well with cell invasiveness (Spearman’s correlation coefficient: 0.943,
P 5 0.0048). On the basis of our earlier findings that EZH2 overex-
pression in benign cells could mediate cell invasion and neoplastic
progression6,10,11, sarcosine levels were assessed on modulation of
EZH2 expression. Interestingly, overexpression of EZH2 in benign
prostate epithelial cells increased sarcosine levels (4.5-fold, Supple-
mentary Fig. 16a), whereas its knockdown in DU145 prostate
cancer cells diminished the levels of the metabolite (Supplementary
Fig. 16a–c). To determine whether sarcosine has a more direct role in
this process, we added the metabolite to non-invasive benign prostate
epithelial cells. Alanine, an isomer of sarcosine, was used as a control for
these experiments. Remarkably, the mere addition of exogenous sarco-
sine imparted an invasive phenotype to benign prostate epithelial cells
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Figure 1 | Metabolomic profiling of prostate cancer. a, Venn diagram of the
total metabolites detected across 42 prostate-related tissues and 110
matched plasma and urine samples. b, Venn diagram of 626 metabolites in
tissues measured across 16 benign adjacent prostate tissues, 12 clinically
localized prostate cancers (PCA) and 14 metastatic prostate cancers (Mets).
c, Heat map representation of unsupervised hierarchical clustering of the
data in b (rows) grouped by sample type (columns). Shades of yellow and
blue represent an increase and decrease of a metabolite, respectively, relative
to the median metabolite levels (see colour scale). d, z-score plots for the data
in b normalized to the mean of the benign prostate samples (truncated at 25
s.d. for clarity, see Supplementary Methods for procedural details).
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Figure 2 | Metabolomic alterations of prostate cancer progression. a, Heat
map showing 87 differential metabolites in PCA relative to benign samples
(Wilcoxon P # 0.05). Localized PCA samples are grouped as (i) low grade
(Gleason 313, 314) or (ii) high grade (Gleason 413, 414). Metastatic
samples are grouped by the site of tissue procurement, namely (iii) soft
tissue, (iv) rib/diaphragm or (v) liver. b, Benign-based z-score plot of named
metabolites from a. Each point represents one metabolite in one sample,
coloured by tissue type (blue, benign; yellow, PCA). c, As in b except for the
comparison between Mets (red) and PCA (yellow), with data represented
relative to the mean of the PCA samples. For clarity, the plots in b and c have
been truncated at 15 standard deviations above the mean of the benign and
PCA samples, respectively.
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(Fig. 3d and Supplementary Fig. 17). Furthermore, the number of
motile prostate epithelial cells was significantly higher on sarcosine
treatment (t-test P 5 6.997 3 1026, n 5 10) compared to alanine-
treated controls (Supplementary Fig. 18). Sarcosine treatment, however,
did not affect the ability of these cells to progress through the different
stages of cell cycle (Supplementary Fig. 19a–d) or impair cell prolifera-
tion (Supplementary Fig. 19e). Notably, glycine, a precursor of sarco-
sine, induced invasion in these cells, although to a lesser degree than
sarcosine (Fig. 3d). This invasion could result from the conversion of
glycine to sarcosine by the enzyme glycine-N-methyltransferase
(GNMT; Fig. 4a).
In addition to GNMT, sarcosine levels are regulated by sarcosine
dehydrogenase (SARDH), the enzyme that converts sarcosine back to
glycine, and dimethylglycine dehydrogenase (DMGDH), which
generates sarcosine from dimethylglycine (Fig. 4a). By virtue of their
ability to control sarcosine levels in cells, these enzymes may assume a
critical role in modulating prostate cancer invasion. To test this hypo-
thesis, a series of RNA-interference-mediated knockdown experiments
were carried out. Attenuation of GNMT (Fig. 4b, Supplementary
Fig. 20) in DU145 prostate cancer cells resulted in a significant reduc-
tion in cell invasion (t-test P 5 0.0073, n 5 3), with a concomitant
threefold decrease in the intracellular sarcosine levels compared to
control non-target short interfering RNA (siRNA)-transfected cells.
Similar knockdown experiments performed in benign RWPE cells
significantly hampered the ability of exogenous glycine (t-test
P 5 0.0082, n 5 3), but not sarcosine, to induce invasion (Supple-
mentary Fig. 21a, b). Comparable loss of cell invasion and reduction
in sarcosine levels were also apparent in DU145 cancer cells on knock-
down of DMGDH (Supplementary Fig. 22a, b). In contrast, knock-
down of SARDH in benign prostate epithelial cells resulted in an
,3-fold increase in endogenous sarcosine levels with a concomitant
.3.5-fold increase in invasion (Fig. 4c and Supplementary Fig. 23).
With the understanding that androgen signalling and ETS family
of genes (ERG, ETV1) fusions are key factors for prostate cancer
progression12, we investigated their role in regulating GNMT and
SARDH. Treatment with androgen for 48 h in VCaP (ERG-positive)
and LNCaP (ETV1-positive) prostate cancer cells resulted in a step-
wise increase in GNMT expression and a concomitant decrease in
SARDH levels, as assessed by digital gene expression and quantitative
polymerase chain reaction (qPCR) (Fig. 4d and Supplementary
Fig. 25e). This finding was supported by chromatin immunopreci-
pitation sequencing (ChiP-Seq), which revealed direct binding of
androgen receptor and ERG to the promoter of GNMT in VCaP cells
(Fig. 4e), whereas only ERG binding was seen on the SARDH
promoter (Fig. 4f). In ETV1-positive LNCaP cells, androgen recep-
tor, but not ERG as expected, was bound to both GNMT and SARDH
promoters (Supplementary Figs 25a, b). The binding data were
validated by ChIP–PCR (Supplementary Figs 24a, b, d and 25c, d),
which additionally revealed weak binding of androgen receptor to the
SARDH promoter in VCaP cells (Supplementary Fig. 24c). These
findings together directly link activation of the sarcosine pathway
to androgen receptor and ETS gene fusion regulation—two key med-
iators of prostate cancer progression. Remarkably, both ERG- and
ETV1-induced invasion were associated with a threefold sarcosine
increase in benign RWPE cells (Fig. 4g). Similarly, knockdown of the



































































































































































Figure 3 | Sarcosine levels in prostate cancer and its association with cell
invasion. a, Sarcosine levels in prostate-cancer-related tissue specimens
(n 5 89). b, Sarcosine levels in post-digital-rectal-exam urine sediments
from men with biopsy-proven prostate cancer (n 5 49) and prostate-biopsy-
negative controls (n 5 44). Asterisks indicate truncated measures.
c, Increased levels of sarcosine (black bars) were found in invasive prostate
cancer cells compared to non-invasive benign prostate epithelial cell lines.
Mean and s.e.m. of sarcosine levels (n 5 3, except for PrEC cells where
n 5 2). Cell invasion (grey bars) was also measured (mean and s.e.m.).
d, Assessment of cell invasiveness of prostate epithelial cells upon exogenous





















































































   



























































































































   
   











 change in invasion 



























































Figure 4 | A role for sarcosine in androgen signalling and prostate cancer
cell invasion. a, Schematic of the sarcosine pathway and its potential link to
prostate cancer. b, Assessment of sarcosine levels and cell invasiveness after
knockdown of GNMT in DU145 cells by RNA interference. c, As in b except
knockdown of SARDH in RWPE cells (n 5 6). d, qRT–PCR analysis of
GNMT and SARDH mRNA expression in androgen-stimulated VCaP cells.
e, Androgen receptor (AR) and ERG binding sites on the promoter of
GNMT, as determined by ChIP-seq. The y axes display the number of reads
in a 25 bp sliding window. f, As in e, except ERG binding sites in the
promoter of SARDH. g, Left, overexpression of ERG or ETV1 in RWPE cells
and measurement of sarcosine levels and cell invasiveness. Right, as in left,
except knockdown of TMPRSS2–ERG in VCaP cells by RNA interference. All
error bars represent mean and s.e.m., n 5 3 unless indicated otherwise.
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resulted in a more than threefold decrease in sarcosine with a similar
decrease in the invasive phenotype (Fig. 4g).
Taken together, we explored the metabolome of prostate cancer
progression. This led to the characterization of metabolomic signa-
tures, which in the context of other molecular alterations may lead to
a more complete understanding of disease progression. Specifically,
we identified sarcosine as a key metabolite increased most robustly in
metastatic prostate cancer and detectable in the urine of men with
organ-confined disease. Interestingly, sarcosine and its proximal
regulatory enzymes seem to have an intermediary role in neoplastic
progression modulating cell invasion and migration. The master
transcriptional regulators of prostate cancer progression, androgen
receptor and the ETS gene fusions, seem to regulate directly sarcosine
levels by means of transcriptional control of its regulatory enzymes.
Thus, components of the sarcosine pathway may have potential as
biomarkers of prostate cancer progression and serve as new avenues
for therapeutic intervention.
METHODS SUMMARY
Biospecimens and associated clinical data related to the study were collected with
written consent from the University of Michigan and approved for use by the
Internal Review Board. Unbiased metabolomic profiling using liquid/gas chro-
matography coupled to mass spectrometry (LC/GC–MS) was performed as
described3 using a Thermofisher linear ion-trap mass spectrometer with Fourier
transform and Mat-95 XP mass spectrometers, respectively (Supplementary Fig. 1).
Target metabolites were assessed in tissue and urine samples using isotope dilution
GC–MS. Metabolomic data analysis is detailed in Supplementary Fig. 4. All
Wilcoxon rank-sum tests and t-tests are two-sided using a threshold of P , 0.05
for significance. Repeated measures ANOVA is used for the cell line data with
P values from the model F-test. Class-specific metabolomic patterns were visualized
using z-score plots and heat maps. Unsupervised clustering of samples using meta-
bolomic signatures was performed using Cluster13 and TreeView14, and visualized
using heat maps. Analysis of network relationships among various molecular con-
cepts and metabolomic data was performed using OCM4,5 (http://www.oncomine.
org), as outlined in Supplementary Fig. 9. Invasion was measured using a modified
Boyden chamber assay as described10. The cell motility assay was performed as
reported previously using blue fluorescent microsphere beads15. Targeted knock-
down of candidate genes16 using gene-specific siRNA sequences are listed in
Supplementary Table 9. qPCR for enzymes regulating sarcosine levels, EZH2 and
ETS, was performed as described12 using the indicated oligonucleotide primers
(Supplementary Table 10). Chromatin immunoprecipitation to interrogate the
regulatory role of androgen and ETS was performed using published protocols17.
ChIP-Seq and digital gene expression were measured using the Genomic DNA
Sample Prep Kit and the NIaIII kit on a Genome Analyser (Illumina) according
to the manufacturer’s instructions.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
Biospecimens and cell lines. Prostate tissues, urine and plasma were obtained
from the University of Michigan SPORE and EDRN Tissue Core. All samples
were collected with informed consent as per the approval of the Institutional
Review Board.
RWPE, DU145, LnCAP and PC3 cells were obtained from ATCC, PrEC cells
from Cambrex BioScience, 22-RV1 was provided by J. Macoska and VCaP by K.
Pienta. VCaP and LnCAP were grown in charcoal-stripped-serum-containing
media for 24 h, before treatment for a further 24 h with vehicle or 1 nM methyl-
trienolone (R1881, NEN) dissolved in ethanol.
Metabolomic profiling. Metabolomic profiling was performed using the plat-
form described previously3 and outlined in Supplementary Fig. 1. The LC–MS
portion of the platform is based on a Surveyor HPLC and a Thermo-Finnigan
LTQ-FT mass spectrometer (Thermo Fisher Corporation) with the instrument set
for continuous monitoring of both positive and negative ions. Samples that were
analysed by GC–MS were derivatized under dried nitrogen using bistrimethyl-
silyl-triflouroacetamide (BSTFA) and analysed on a Thermo-Finnigan Mat-95 XP
using electron impact ionization and high resolution. For both LC–MS and GC–
MS, spectral files were searched using metabolomic libraries created by Metabolon
that contain about 800 commercially available compounds.
Quantification of target metabolites was performed by isotope dilution GC–
MS using selected ion monitoring (SIM). The samples were modified to their
t-butyl dimethylsilyl derivatives and analysed with an Agilent 5975 MSD mass
detector using electron impact ionization. For SIM analysis, the m/z for native
and labelled molecular peaks for various target metabolites quantified were: 158
and 161 (sarcosine), 406 and 407 (cysteine), 432 and 437 (glutamic acid), 297
and 301 (thymine) and 218 and 219 (glycine), respectively. Assessment of citric
acid was performed on the GC–MS in the full scan mode.
Statistical analysis. Missing metabolite measurements were replaced (imputed)
with zero for metabolites where the mean relative standardized intensity measure
was over 100,000 across the samples, that is, we assume missingness was probably
due to absence of the metabolite in the sample. Otherwise one half of the sample
minimum was used to replace the missing measurement, that is, we assume miss-
ingness was probably due to detection limits. Imputed data were median-centred
and inter-quartile-range-scaled per sample. Plotted z-scores were calculated based
on the mean and standard deviation of a reference set (benign samples, unless
otherwise stated). Hierarchical clustering14 based on Pearson’s correlation was
performed on the log-transformed normalized data after median centring per
metabolite. A small value (unity) was added to each normalized value to allow
log transformation. Per-metabolite chi-squared tests were used to assess class-
specific metabolite patterns of present and absent (undetected) measurements.
Per-metabolite two-tailed Wilcoxon rank sum tests were used for two-sample tests
of association between classes. Kruskal–Wallis tests were used for three-way com-
parisons between all diagnosis groups. Non-parametric tests were chosen to reduce
the influence of the imputed values. Tests were run on those metabolites with
detectable expression in at least 20% of the samples. Significance was determined
using 1,000 sample permutations. FDRs were calculated using the q-value conversion
algorithm of ref. 18. Pairwise differences in expression in the cell line data and small-
scale tissue data were tested using two-tailed t-tests with Satterthwaite variance
estimation. Comparisons involving multiple cell lines used repeated measures
ANOVA to adjust for the multiple measures per cell line. Fold change was estimated
using ANOVA on a log scale, following the model log(Y) 5 A 1 B*treatment 1 E. In
this way exp(B) is an estimate of (Y j treatment 5 1)/(Y j treatment 5 0), and the
standard error of exp(B) can be estimated from SE(B) using the delta method. The
threshold for significance was P , 0.05 for all tests.
ChIP-PCR. ChIP was carried out as described previously19 using antibodies against
androgen receptor (Millipore), ERG (Santa Cruz) and rabbit IgG (Santa Cruz).
Androgen receptor ChIP was performed in paired ethanol-treated and R1881-
treated samples. ChIP-enriched chromatin as well as the whole-cell extract was
amplified by ligation-mediated PCR. When examining androgen receptor binding
on target genomic regions, equal amounts of ethanol-treated and R1881-treated
ChIP amplicons were subjected to qPCR, and the fold enrichment (R1881/ethanol)
was determined based on the cycle differences after normalization to input DNA.
For ERG ChIP assays, VCaP cells grown in regular medium were used for ChIP
using antibodies against ERG and rabbit IgG control. ChIP products were directly
analysed by the qPCR assay, and ERG binding was evaluated based on the cycle
difference between ChIP-enriched chromatin by ERG and corresponding IgG. The
primers used are listed in Supplementary Table 9.
ChIP-Seq. ChIP samples were prepared for sequencing using the Genomic DNA
Sample Prep kit following the manufacturer’s protocols. ChIP-sequencing was
performed using Illumina Genome Analyser according to standard manufac-
turer’s procedures. The raw sequencing image data were analysed by our analysis
pipeline and aligned to the unmasked human reference genome (NCBI v36,
hg18) using ELAND software to generate sequence reads of 25–32 base pairs.
Digital gene expression analysis. Trizol-extracted RNA from samples with 0 h
and 48 h androgen treatment was prepared for sequencing using the Digital Gene
Expression-Tag Profiling with NIaIII kit (Illumina) and sequenced by the
Genome Analyser. Sequencing reads were mapped back to the human reference
genome using the ELAND software. The number of sequencing reads for genes of
interest was counted. The expression level of each gene was measured as the
number of transcripts per million of total sequencing reads.
Quantitative RT–PCR. qPCR was performed using SYBR Green Mastermix on
an Applied Biosystems 7300 PCR machine as described previously19. All primers
were designed using Primer 3 and synthesized by Integrated DNA Technologies,
and are listed in Supplementary Table 9.
RNA interference. DU145 or RWPE cells were treated with non-targeting siRNA
(Dharmacon) and gene-specific siRNA sequences as listed in Supplementary
Table 10.
Cell invasion assay. Cell invasion assays were carried out using a modified
basement membrane chamber assay as described previously19.
Cell motility assay. For cell motility assays, we used the Cellomics cell motility
kit as per manufacturer’s instructions.
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